Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $906.54 in the prior trading day, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) closed at $890.68, down -1.75%. In other words, the price has decreased by -$1.75 from its previous closing price. On the day, 0.58 million shares were traded. REGN stock price reached its highest trading level at $915.0 during the session, while it also had its lowest trading level at $877.13.
Ratios:
Our goal is to gain a better understanding of REGN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.01 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.23. For the most recent quarter (mrq), Quick Ratio is recorded 4.94 and its Current Ratio is at 5.69. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Bernstein on March 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $1125.
On January 12, 2024, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $884 to $1076.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $800.Deutsche Bank initiated its Hold rating on November 09, 2023, with a $800 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 01 ’24 when McCourt Marion sold 250 shares for $964.73 per share. The transaction valued at 241,182 led to the insider holds 13,181 shares of the business.
RYAN ARTHUR F sold 100 shares of REGN for $96,253 on Apr 01 ’24. The Director now owns 18,182 shares after completing the transaction at $962.53 per share. On Mar 14 ’24, another insider, MURPHY ANDREW J, who serves as the EVP Research of the company, sold 5,783 shares for $956.47 each. As a result, the insider received 5,531,290 and left with 48,306 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 99503202304 and an Enterprise Value of 87659962368. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.63, and their Forward P/E ratio for the next fiscal year is 18.63. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.48. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.45 while its Price-to-Book (P/B) ratio in mrq is 3.75. Its current Enterprise Value per Revenue stands at 6.683 whereas that against EBITDA is 18.835.
Stock Price History:
Over the past 52 weeks, REGN has reached a high of $998.33, while it has fallen to a 52-week low of $684.80. The 50-Day Moving Average of the stock is -6.26%, while the 200-Day Moving Average is calculated to be 3.29%.
Shares Statistics:
The stock has traded on average 463.51K shares per day over the past 3-months and 500680 shares per day over the last 10 days, according to various share statistics. A total of 107.60M shares are outstanding, with a floating share count of 105.09M. Insiders hold about 4.26% of the company’s shares, while institutions hold 84.65% stake in the company. Shares short for REGN as of 1713139200 were 1387154 with a Short Ratio of 2.99, compared to 1710460800 on 1392439. Therefore, it implies a Short% of Shares Outstanding of 1387154 and a Short% of Float of 1.5.
